GSK’s Ris-Rez shows 61% response rate in small cell lung cancer trial
Summary
A recent trial indicates that the pharmaceutical product Ris-Rez, developed by GSK, achieved a response rate of sixty-one percent in patients with small cell lung cancer. This early finding highlights the performance of the treatment during clinical evaluation.
Source: Read the full story at Stock Market News
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.